MA54095A - Formulations pharmaceutiques aqueuses - Google Patents

Formulations pharmaceutiques aqueuses

Info

Publication number
MA54095A
MA54095A MA054095A MA54095A MA54095A MA 54095 A MA54095 A MA 54095A MA 054095 A MA054095 A MA 054095A MA 54095 A MA54095 A MA 54095A MA 54095 A MA54095 A MA 54095A
Authority
MA
Morocco
Prior art keywords
pharmaceutical formulations
aqueous pharmaceutical
aqueous
formulations
pharmaceutical
Prior art date
Application number
MA054095A
Other languages
English (en)
Inventor
Wen-Cheng Chang
Jiung-Liang Liu
Jheng-Gang Yang
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of MA54095A publication Critical patent/MA54095A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MA054095A 2018-10-31 2019-10-24 Formulations pharmaceutiques aqueuses MA54095A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862753084P 2018-10-31 2018-10-31

Publications (1)

Publication Number Publication Date
MA54095A true MA54095A (fr) 2022-02-09

Family

ID=70463495

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054095A MA54095A (fr) 2018-10-31 2019-10-24 Formulations pharmaceutiques aqueuses

Country Status (11)

Country Link
US (1) US20210393783A1 (fr)
EP (1) EP3873437A4 (fr)
JP (2) JP7411652B2 (fr)
KR (1) KR20210094552A (fr)
AU (1) AU2019372568A1 (fr)
BR (1) BR112021008155A2 (fr)
CA (1) CA3117245A1 (fr)
IL (1) IL282343A (fr)
MA (1) MA54095A (fr)
MX (1) MX2021005015A (fr)
WO (1) WO2020088346A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021015034A2 (pt) 2019-02-18 2021-10-05 Eli Lilly And Company Formulação de anticorpo terapêutico
CN115605184A (zh) * 2020-05-15 2023-01-13 豪夫迈·罗氏有限公司（Ch） 防止胃肠外蛋白质溶液中的可见颗粒形成

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3417B1 (ar) * 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
AR080428A1 (es) * 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
JP2013541594A (ja) 2010-11-08 2013-11-14 ジェネンテック， インコーポレイテッド 皮下投与される抗ｉｌ−６受容体抗体
BR112018017031A2 (pt) * 2016-02-23 2019-01-22 Sesen Bio Inc formulações de antagonista de il-6 e usos das mesmas
CA3037440A1 (fr) * 2016-09-27 2018-04-05 Fresenius Kabi Deutschland Gmbh Composition pharmaceutique liquide
KR20190078572A (ko) 2016-10-31 2019-07-04 프레제니우스 카비 도이치란트 게엠베하 액상의 약학 조성물
CN107760760A (zh) * 2017-09-28 2018-03-06 中国食品药品检定研究院 一种快速测定il‑6/il‑6受体抗体药物生物学活性的方法

Also Published As

Publication number Publication date
CA3117245A1 (fr) 2020-05-07
JP7411652B2 (ja) 2024-01-11
JP2024041791A (ja) 2024-03-27
KR20210094552A (ko) 2021-07-29
MX2021005015A (es) 2021-07-21
EP3873437A1 (fr) 2021-09-08
JP2022506042A (ja) 2022-01-17
EP3873437A4 (fr) 2022-08-03
AU2019372568A1 (en) 2021-05-20
US20210393783A1 (en) 2021-12-23
WO2020088346A1 (fr) 2020-05-07
BR112021008155A2 (pt) 2021-08-10
IL282343A (en) 2021-05-31

Similar Documents

Publication Publication Date Title
MA52421A (fr) Composés pharmaceutiques
MA54714A (fr) Formulation de nicotine
DK3688162T3 (da) Formuleringer
MA50541A (fr) Formulations pharmaceutiques
MA46466A (fr) Formulations pharmaceutiques de protéines à viscosité réduite
DK3386541T3 (da) Vandig farmaceutisk formulering omfattende anti-pd-1-antistof avelumab
MA46867A (fr) Formulations pharmaceutiques
MA42303A (fr) Formulations pharmaceutiques
DK3634377T3 (da) Farmaceutisk formulering
MA50657A (fr) Formulations de niraparib
MA55015A (fr) Formulations pharmaceutiques
MA54716A (fr) Réduction de la viscosité de formulations pharmaceutiques
MA45187A (fr) Combinaisons pharmaceutiques
DK3709978T3 (da) Farmaceutisk oral formulering omfattende bakterier
DK3244878T3 (da) Faste orale sammensætningsformer
MA49837A (fr) Compositions pharmaceutiques
MA43705A (fr) Formulation pharmaceutique
MA44987A (fr) Formulations de médicaments améliorées
DK3870234T3 (da) Antistoflægemiddelkonjugater omfattende ecteinascidinderivater
ZA202006570B (en) Pharmaceutical formulations
SG11202010124SA (en) Stable pharmaceutical formulation
DK3583943T3 (da) Farmaceutisk sammensætning
MA49977A (fr) Combinaisons pharmaceutiques comprenant un anticorps anti-ly75
MA44079A (fr) Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine
DK3762009T3 (da) Toxin-afledte indgivelseskonstrukter til oral indgivelse